Keyphrases
Crohn's Disease
100%
Monotherapy
100%
Adalimumab
77%
Combotherapy
44%
Infliximab
33%
Infliximab Therapy
22%
Vedolizumab
22%
Israeli
11%
Inflammatory Bowel Disease
11%
Propensity Score Matching
11%
Methotrexate
11%
Combination Therapy
11%
Anti-tumor Necrosis Factor (anti-TNF)
11%
Thiopurines
11%
Time-to-event Analysis
11%
Medicine and Dentistry
Monotherapy
100%
Patient with Crohn's Disease
100%
Adalimumab
63%
Biological Product
54%
Infliximab
45%
Crohn's Disease
27%
Vedolizumab
18%
Combination Therapy
9%
Inflammatory Bowel Disease
9%
Drug Therapy
9%
Tumor Necrosis
9%
Methotrexate
9%
Mercaptopurine
9%
Propensity Score Matching
9%
Immunology and Microbiology
Crohn's Disease
100%
Adalimumab
100%
Biological Product
85%
Infliximab
71%
Vedolizumab
28%
Tumor Necrosis Factor
14%
Inflammatory Bowel Disease
14%
Methotrexate
14%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Monotherapy
100%
Adalimumab
63%
Biological Product
54%
Infliximab
45%
Vedolizumab
18%
Inflammatory Bowel Disease
9%
Combination Therapy
9%
Tumor Necrosis
9%
Mercaptopurine
9%
Methotrexate
9%